… , characterizations of treatment response of pulmonary RRP are currently lacking in the …
pulmonary RRP patients receiving systemic bevacizumab, and show that systemic bevacizumab …

… It is not clear from most reports if pulmonary function … that pulmonary function can improve
with systemic bevacizumab. … lung parenchymal involvement was associated with pulmonary …

… also seen in the first case report of systemic bevacizumab for pulmonary RRP.4 A similar
result was reported recently in the United States literature, describing the impact of intravenous …

… bevacizumab with a medical oncologist. A pediatric pulmonologist is part of the multidisciplinary
team for those patients with diagnosed pulmonary … is tracheal or pulmonary involvement. …

… Lung cancer developed in one patient with pulmonary papillomatosis prior to bevacizumab
administration whereas three patients suffered from malignant transformation during …

… Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe
pulmonary … potential adverse event associated with bevacizumab therapy for advanced non-…

… Systemic bevacizumab could not be given because of financial constraints. After the first
cycle, she declined further chemotherapy and was therefore started on oral gefitinib. She was …

… not reported with single-agent bevacizumab. We observed enhanced pulmonary parenchymal
toxicity during treatment with bevacizumab concurrent with radiation, a finding that, to the …

… papilloma following systemic administration of bevacizumab. … papillomatosis treated with
systemic bevacizumab. All patients … used systemic bevacizumab for extensive pulmonary and …

… response of pulmonary RRP to systemic bevacizumab was the … —any level of control of
pulmonary RRP should be considered a … systemic bevacizumab represents an effective adjuvant …